154 related articles for article (PubMed ID: 35023411)
1. Nephrotic syndrome induced by cetuximab in a patient with metastatic colorectal cancer.
Korkmaz M; Hendem E; Karakurt Eryılmaz M; Demirkıran A; Karaağaç M; Artaç M
J Oncol Pharm Pract; 2022 Jun; 28(4):998-1002. PubMed ID: 35023411
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab-induced nephrotic syndrome in a case of metastatic rectal cancer.
Ito C; Fujii H; Ogura M; Sato H; Kusano E
J Oncol Pharm Pract; 2013 Sep; 19(3):265-8. PubMed ID: 23047237
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
4. Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment.
Saito Y; Uchiyama K; Takekuma Y; Komatsu Y; Sugawara M
Support Care Cancer; 2023 Aug; 31(8):504. PubMed ID: 37528282
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
7. [Nephrotic Syndrome Induced by Ramucirumab for Metastatic Rectal Cancer].
Sakabe R; Shirakawa K; Yoshimura K; Otsuka H; Kuwada A; Tahara K; Hotei H; Maeda Y
Gan To Kagaku Ryoho; 2018 Aug; 45(8):1205-1207. PubMed ID: 30158421
[TBL] [Abstract][Full Text] [Related]
8. [The efficacy of cetuximab for metastatic colorectal cancer].
Katsumoto Y; Aritake N; Endoh A
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2523-5. PubMed ID: 21224627
[TBL] [Abstract][Full Text] [Related]
9. Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer.
Dotan E; Devarajan K; D'Silva AJ; Beck A; Kloth DD; Cohen SJ; Denlinger C
Clin Colorectal Cancer; 2014 Sep; 13(3):192-8. PubMed ID: 25074246
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
11. Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report.
Gürbüz M; Akkuş E; Utkan G
J Oncol Pharm Pract; 2021 Mar; 27(2):480-484. PubMed ID: 32623964
[TBL] [Abstract][Full Text] [Related]
12. Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody-Induced Skin Fissure: A Single Institutional Case Series.
Okunaka M; Kotani D; Mishima S; Nakamura M; Kawazoe A; Bando H; Yoshino T; Shitara K
Integr Cancer Ther; 2024; 23():15347354231225962. PubMed ID: 38240253
[TBL] [Abstract][Full Text] [Related]
13. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
[TBL] [Abstract][Full Text] [Related]
14. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
Zhang W; Gordon M; Lenz HJ
Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
[TBL] [Abstract][Full Text] [Related]
15. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
Xu W; Jing H; Zhang F
Front Biosci (Landmark Ed); 2016 Jan; 21(2):410-8. PubMed ID: 26709782
[TBL] [Abstract][Full Text] [Related]
17. A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.
Wierzbicki R; Jonker DJ; Moore MJ; Berry SR; Loehrer PJ; Youssoufian H; Rowinsky EK
Invest New Drugs; 2011 Feb; 29(1):167-74. PubMed ID: 19830388
[TBL] [Abstract][Full Text] [Related]
18. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.
Wen F; Li Q
World J Gastroenterol; 2016 Jun; 22(23):5332-41. PubMed ID: 27340349
[TBL] [Abstract][Full Text] [Related]
19. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
Lien K; Berry S; Ko YJ; Chan KK
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):81-100. PubMed ID: 25400031
[TBL] [Abstract][Full Text] [Related]
20. A case of psoriasis pustolosa palmaris induced by cetuximab.
Marinello E; Pastorelli D; Alaibac M
BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 26994052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
